PTN
Palatin Technologies, Inc. Common Stock
stockNASDAQ
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 9.58 | 2026-09-28 | -0.83% | 7.440 |
| 1M | 12.70 | 2026-09-04 | -25.20% | 2.680 |
| 3M | 11.01 | 2026-07-06 | -13.71% | 0.493 |
| 6M | 18.03 | 2026-04-06 | -47.31% | 0.327 |
| 1Y | 11.04 | 2025-11-12 | -13.95% | 0.041 |
| 2Y | 0.88 | 2024-10-04 | +975.76% | — |
| 5Y | 10.75 | 2021-10-04 | -11.63% | 0.062 |
Palatin Technologies, Inc. Common Stock (NASDAQ:PTN) stock price today is $9.50, and today's volume is 17,289. PTN is up 4.857% today. The 30 day average volume is 113,291. PTN market cap is $16.92M with 1.78M shares outstanding.